Loading...
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
Imatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data f...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2008
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2954751/ https://ncbi.nlm.nih.gov/pubmed/18664621 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-02-141689 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|